KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares Issued
Ratios

Jazz Pharmaceuticals (JAZZ) Long-Term Debt Repayments (2020 - 2021)

Historic Long-Term Debt Repayments for Jazz Pharmaceuticals (JAZZ) over the last 2 years, with Q3 2021 value amounting to $218.8 million.

  • Jazz Pharmaceuticals' Long-Term Debt Repayments rose 83910.73% to $218.8 million in Q3 2021 from the same period last year, while for Dec 2023 it was $218.8 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $575.0 million for FY2024, which is N/A changed from last year.
  • As of Q3 2021, Jazz Pharmaceuticals' Long-Term Debt Repayments stood at $218.8 million, which was up 83910.73% from $23.3 million recorded in Q3 2020.
  • Jazz Pharmaceuticals' Long-Term Debt Repayments' 5-year high stood at $218.8 million during Q3 2021, with a 5-year trough of $23.3 million in Q3 2020.